Women’s Best Choice For PCOS Support

Clinical Research Behind Orbelli

Orbelli is formulated using ingredients that have been independently studied in human clinical research for their role in hormonal signaling, insulin sensitivity, cycle regularity, energy metabolism, and mood-related pathways commonly affected in PCOS and hormone-related imbalance.

The evidence below reflects ingredient-level human studies, not trials conducted on the finished Orbelli formulation.

Supports Cycle Regularity & Hormonal Signaling

Human clinical trials evaluating myo-inositol and D-chiro-inositol show improvements in hormonal markers and menstrual regularity when taken daily over 8–24 weeks.

• A meta-analysis of 9 randomized controlled trials (496 women) reported significant decreases in fasting insulin and HOMA index, with increased SHBG observed after 24 weeks of myo-inositol supplementation in women with PCOS. PubMed: https://pubmed.ncbi.nlm.nih.gov/29042448/ 
• A 3-month open prospective study using a 40:1 myo-inositol to D-chiro-inositol ratio showed significant reductions in free testosterone, free androgen index, and LH levels, with improved metabolic parameters in PCOS phenotype A patients. PubMed: https://pubmed.ncbi.nlm.nih.gov/38295772/ 
• A systematic review and meta-analysis of 30 trials (2,230 women) conducted to inform the 2023 international PCOS guidelines found evidence of benefits for myo-inositol and D-chiro-inositol on some metabolic measures and potential benefits from DCI for ovulation. PubMed: https://pubmed.ncbi.nlm.nih.gov/38163998/ 

Supports Blood Sugar Balance & Insulin Sensitivity

Clinical studies on inositols and chromium demonstrate improvements in glucose metabolism and insulin signaling with consistent daily supplementation over 4–12 weeks.

• A meta-analysis of 10 randomized controlled trials (683 women) found that chromium supplementation significantly decreased fasting blood insulin, triglycerides, total cholesterol, VLDL, LDL, hs-CRP, and increased insulin sensitivity (QUICKI) in women with PCOS. PubMed: https://pubmed.ncbi.nlm.nih.gov/41067797/ 
• A systematic review and meta-analysis of 7 studies showed that chromium picolinate supplementation had beneficial effects on decreasing BMI, fasting insulin, and free testosterone in PCOS patients. PubMed:https://pubmed.ncbi.nlm.nih.gov/28595797/
• An 8-week randomized, double-blind, placebo-controlled trial in 64 women with PCOS showed that 200 µg/day chromium picolinate significantly decreased serum insulin, HOMA-IR, and HOMA-B compared to placebo.PubMed: https://pubmed.ncbi.nlm.nih.gov/26279073/ 

Supports Weight Regulation & Energy Metabolism

Human trials evaluating L-carnitine report support for fat metabolism, mitochondrial energy production, and reductions in body weight and metabolic markers over 8–12 weeks.

• A systematic review and meta-analysis of RCTs in women with PCOS found low to moderate certainty evidence that L-carnitine improves BMI and serum LDL, triglyceride, and total cholesterol levels. PubMed:https://pubmed.ncbi.nlm.nih.gov/36132218/ 
• A 12-week randomized, double-blind, placebo-controlled trial in 60 overweight women with PCOS showed that carnitine supplementation resulted in significant reductions in weight (−2.7 kg), BMI, waist circumference, and improvements in glycemic control. PubMed: https://pubmed.ncbi.nlm.nih.gov/26666519/ 
• A meta-analysis found that carnitine supplementation significantly improved ovulation rates (RR 3.42) and pregnancy rates in women with PCOS, alongside improvements in insulin resistance and BMI. PubMed:https://pubmed.ncbi.nlm.nih.gov/36746677/
• A 12-week randomized, double-blind, controlled trial in 62 overweight/obese women with PCOS found that 1,000 mg/day L-carnitine significantly improved insulin levels, HOMA-IR, and SHBG compared to placebo. PubMed:https://pubmed.ncbi.nlm.nih.gov/34727201/ 

Supports Skin Clarity & Androgen-Related Balance

Human studies evaluating zinc and inositol-based supplementation suggest improvements in skin appearance and hormone-related androgen markers over 8–12 weeks.

• A systematic review and meta-analysis found that acne patients have significantly lower serum zinc levels than controls, and that zinc supplementation significantly improved inflammatory papule count when used as monotherapy or adjunctive treatment. PubMed: https://pubmed.ncbi.nlm.nih.gov/32860489/ 
• A systematic review of 22 studies found zinc supplementation to be beneficial in 10 of 14 studies evaluating its effects on acne vulgaris, supporting its role as an anti-inflammatory agent for skin conditions. PubMed:https://pubmed.ncbi.nlm.nih.gov/31745908/ 
• An 8-week randomized, double-blind, placebo-controlled trial in 48 women with PCOS found that 50 mg/day zinc supplementation had beneficial effects on alopecia, hirsutism, and plasma MDA (oxidative stress) levels. PubMed:https://pubmed.ncbi.nlm.nih.gov/26315303/ 
• A 3-month study using a 40:1 myo-inositol to D-chiro-inositol ratio showed significant reductions in free testosterone and improved hormone ratios in PCOS populations. PubMed:https://pubmed.ncbi.nlm.nih.gov/38295772/ 

Supports Daily Energy & Endocrine Function

Clinical research on selenium, folate, and B-vitamins highlights their role in endocrine signaling, energy regulation, and hormonal pathways when used consistently.

• A comprehensive literature review confirmed selenium's essential role in thyroid hormone metabolism and antioxidant defense, with supplementation associated with reduced thyroid peroxidase antibody levels and improved thyroid ultrasound features. PubMed (full text): https://pmc.ncbi.nlm.nih.gov/articles/PMC5307254/ 
• A systematic review and meta-analysis of 35 RCTs in patients with Hashimoto thyroiditis found that selenium supplementation was associated with reduced serum TSH and TPOAb levels, with confirmed safety at doses ranging from 80 to 400 µg/day for up to 12 months. PubMed: https://pubmed.ncbi.nlm.nih.gov/38243784/ 
• An 8-week randomized, double-blind, placebo-controlled trial in 64 women with PCOS showed that selenium supplementation (200 µg/day) had beneficial effects on pregnancy rates, reduced DHEA and hirsutism scores, and decreased inflammatory markers (hs-CRP) and oxidative stress (MDA). PubMed:https://pubmed.ncbi.nlm.nih.gov/26267328/ 
• A review of clinical evidence found that folic acid supplementation may reduce homocysteine levels in PCOS women, potentially improving metabolic profiles and ameliorating hallmark features of the condition, with growing evidence that folate and vitamin B12 are beneficial to fertility. PubMed:https://pubmed.ncbi.nlm.nih.gov/36165609/ 
• An 8-week randomized, double-blind, placebo-controlled trial in 81 obese women with PCOS showed that 5 mg/day folate supplementation had beneficial effects on glucose metabolism and lipid profiles. PubMed:https://pubmed.ncbi.nlm.nih.gov/24828019/ 

Combined Micronutrient Supplementation

Research evaluating multi-nutrient approaches shows synergistic benefits when combining ingredients relevant to hormonal health.

• A randomized, controlled, double-blinded trial in 60 women with PCOS found that a standardized micronutrient supplementation (including folic acid, selenium, vitamin E, and co-enzyme Q10) for 3 months significantly improved the LH:FSH ratio, serum testosterone, and AMH levels. PubMed:https://pubmed.ncbi.nlm.nih.gov/31101977/ 
• A network meta-analysis of 41 RCTs (2,362 patients) comparing nutritional supplements in PCOS found that carnitine, inositol, and probiotics were most effective for reducing body weight and BMI, while chromium and selenium showed benefits for improving glucose metabolism. PubMed:https://pubmed.ncbi.nlm.nih.gov/38025704/ 

Designed for Consistent, Long-Term Use

Across published clinical research, meaningful hormonal and metabolic changes are most often observed after 8–12 weeks or longer of consistent daily supplementation.

Orbelli is formulated to align with these evidence-based timelines, prioritizing steady support rather than short-term intervention.

Scientific Disclosure

Orbelli is a dietary supplement formulated using ingredients supported by published human clinical research. The studies referenced evaluate individual ingredients and mechanisms and do not represent clinical trials conducted on the finished Orbelli formulation. Orbelli is not intended to diagnose, treat, cure, or prevent any disease.